The FDA approved Pfizer's biosimilar Ixifi on Wednesday.
Here are three things to know.
1. Ixifi is a biosimilar version of Johnson & Johnson's immunosuppressive drug Remicade.
2. The drug is intended to treat rheumatoid arthritis, Crohn's disease and plaque psoriasis, among other illnesses.
3. Both Ixifi and Remicade contain a boxed warning over an increased risk of serious infections and cancer.